Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News KaloBios Pharmaceuticals, Inc. KBIO

Healthcare Biotechnology
"KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The company focuses on developing medicines for patients with neglected and rare diseases through innovative and responsible business models."

Recent & Breaking News (OTCPK:KBIO)

KaloBios Provides First Quarter 2014 Financial Results

PR Newswire May 8, 2014

Ted W. Love, M.D., Named Chairman of the Board of KaloBios

PR Newswire May 6, 2014

KaloBios Announces Upcoming Participation at Needham Healthcare Conference

PR Newswire April 3, 2014

KaloBios Announces Fiscal Year 2013 Financial Results

PR Newswire March 13, 2014

KaloBios Announces Upcoming Participation at ROTH and BioCentury's Future Leaders in the Biotech Industry Conferences

PR Newswire March 10, 2014

KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies

PR Newswire February 11, 2014

KaloBios Announces Upcoming Webcasts and Conference Participation

PR Newswire February 5, 2014

Five Star Equities Issues New Research Reports on FLEX, KBIO, NSR and SYMC

Accesswire February 5, 2014

KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma

PR Newswire January 29, 2014

Epidemiological Study on Ventilator-Associated Pneumonia Incidence Reported at Critical Care Congress, Announces KaloBios

PR Newswire January 13, 2014

KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing

PR Newswire January 7, 2014

KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody

PR Newswire December 10, 2013

KaloBios Receives Notice of Allowance for Key Composition of Matter Patent Covering KBOO4

PR Newswire December 5, 2013

KaloBios Reports Third Quarter 2013 Financial Results

PR Newswire November 12, 2013

KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH

PR Newswire November 7, 2013

U.S. FDA Grants Orphan Drug Designation for KaloBios' KB001-A in Treatment of Cystic Fibrosis Patients

PR Newswire October 30, 2013

KaloBios Elects Laurie Smaldone Alsup, M.D. to Board

PR Newswire October 23, 2013

KaloBios Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire October 1, 2013

KaloBios to Present at Leerink Swann Rare Disease Roundtable

PR Newswire September 30, 2013

KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock

PR Newswire September 26, 2013